PIB TrackerIndia's whole nanomedicine portfolio is smaller than one start-up cheque
The Department of Biotechnology funds 210 nanomedicine projects with Rs 174 crore - about Rs 83 lakh each. Four days ago a single firm received Rs 285 crore.
What happened
- Dr Jitendra Singh inaugurated the World Congress on Nanomedicine 2026 at Vigyan Bhawan, hosted by the Institute of Nano Medical Sciences, University of Delhi - over 2,000 participants.
- DBT is supporting 210 R&D projects in nanomedicine with Rs 174 crore.
- Nobel Laureate Prof. Roger D. Kornberg (Stanford) is Chairperson; Prof. T.M.S. Chang (McGill) is Honorary President.
- A regulatory framework for nanopharmaceuticals exists in guidelines from DBT, ICMR and CDSCO; start-ups are supported through BIRAC.
- The Minister cautioned against excessive dependence on technology - AI and nanotech must complement clinical sense, not compromise it.
For Prelims
- Nanomedicine: nanotechnology applied to medicine, working at about one-billionth of a metre. Its promise is delivering the right dose to the right place at the right time - raising effectiveness while cutting toxicity.
- Why oral insulin is hard: insulin is a protein, so digestive enzymes destroy it and absorption across the gut wall fails. Nanoparticle carriers are an attempt to solve both, and the Minister explicitly named the earlier failures.
- The three regulators in one framework: DBT (research), ICMR (biomedical research policy) and CDSCO (drug approval) jointly issued the nanopharmaceutical guidelines for safety, quality and efficacy.
- BIRAC: the Biotechnology Industry Research Assistance Council, DBT's translation arm. Its named schemes are BIG (Biotechnology Ignition Grant), PACE, SBIRI and BIPP.
- Nanotoxicology: one of the funded project areas. A particle small enough to cross a cell membrane is also small enough to cross barriers you did not intend - which is why toxicology and regulatory science sit inside the research portfolio, not after it.
- Precision medicine: treatment matched to a patient's genetic profile, lifestyle, diet and environment. The same diagnosis may warrant different treatment - which is what nanoscale delivery is meant to make practical.
- The hosts: the Congress runs under the International Society of Nano Medical Sciences (ISNS) and the International Society for Nano Medicine (ISNM).
- Also present: Prof. Gobardhan Das, Member, NITI Aayog, and Prof. Yogesh Singh, Vice-Chancellor, University of Delhi.
For UPSC: The funding arithmetic is the transferable part. Use this on research funding and the gap between breadth and depth, on India's biotechnology and regulatory architecture where DBT, ICMR, CDSCO and BIRAC each have a distinct role, and on technology in healthcare delivery - where a technology minister arguing for the primacy of clinical examination is a quotable position, not a throwaway line.
What it is NOT: No output figures appear for the 210 projects - no patents, publications, clinical trials entered or products approved - so a portfolio can be sized but not assessed. No timeframe is given for the Rs 174 crore: whether it is annual, cumulative or committed over several years changes the average by an order of magnitude. No count of nanopharmaceutical products actually approved under the DBT-ICMR-CDSCO guidelines, and no number of nanomedicine start-ups funded through BIRAC. Oral insulin and breast-cancer nanobots are named without a stage, institution or trial status. And no comparison is offered with what other countries spend, in a speech whose claim is that India's indigenous research carries global potential.
For Mains
Syllabus: GS3.13 · GS3.12 · Linkage L2
Anchor
The Department of Biotechnology supports 210 nanomedicine research projects with Rs 174 crore. That is about Rs 83 lakh a project. In the same week, the Research Development and Innovation Fund disbursed Rs 285 crore to a single electric-aircraft start-up, Rs 200 crore to a launch-vehicle firm and Rs 63.84 crore to a satellite-imaging company. One of those cheques is larger than the entire national portfolio in a field the Minister calls the next generation of medicine.
Substantiation (data)
The portfolio is broad: targeted drug delivery, cancer nanomedicine, infectious-disease nanomedicine, nucleic-acid and vaccine delivery, nano-diagnostics and imaging, regenerative medicine and wound healing, and nanotoxicology and regulatory science. The institutional scaffolding is real too - BIRAC schemes for translation, and a nanopharmaceutical regulatory framework already written jointly by DBT, ICMR and CDSCO. The Congress itself drew over 2,000 participants with a Nobel Laureate in the chair.
Position
The Minister's caution is the most valuable thing in the release, and it comes from an unexpected direction. A technology minister at a technology congress arguing that AI and nanotechnology must complement rather than compromise clinical sense, and that observation and physical examination must survive the reinvention of medical teaching, is making a point about deskilling that health policy usually leaves to clinicians. Diagnostic capital is unevenly distributed; clinical judgement is the part that travels to a district hospital.
Counterpoint
Breadth at Rs 83 lakh a project buys literature, not translation. Nanomedicine is capital-intensive at exactly the stage the portfolio must eventually reach - toxicology packages, GMP manufacture, clinical trials - and none of that happens at this ticket size. Spreading Rs 174 crore across 210 projects funds a research community; concentrating it would fund a product. The release offers no evidence on which choice is being made deliberately.
Problematisation
Set the two instruments side by side and an implicit policy appears: deep-tech hardware is financed in hundreds of crores through convertible debentures to firms, while health research is financed in lakhs through grants to laboratories. Aerospace has a visible buyer and a demonstrable milestone; a drug-delivery platform has neither for a decade. The state is funding what it can watch, and that is a selection criterion nobody has argued for.
Conclusion
The regulatory framework is in place before the products are, which is the right order and rarely how it goes. What is missing is the money to get a candidate from a laboratory to a trial. Until nanomedicine gets an instrument like the RDI Fund rather than a grant programme, India will keep publishing in a field it says it intends to lead.
Deploys into: Research funding: breadth against depth · DBT, ICMR, CDSCO and BIRAC in the biotech chain · Precision and personalised medicine · Technology and deskilling in clinical practice
Ministry of Science and Technology · 2026-09-27 · PRID 2315531 · PIB source ↗